Skip to main content
Top
Published in: Current Gastroenterology Reports 4/2013

01-04-2013 | Esophagus (L Gerson, Section Editor)

Ambulatory Reflux Monitoring in GERD – Which Test Should be Performed and Should Therapy be Stopped?

Authors: Andrew J. Gawron, John E. Pandolfino

Published in: Current Gastroenterology Reports | Issue 4/2013

Login to get access

Abstract

Diagnosing gastroesophageal reflux disease (GERD) often entails using a combination of patient symptoms, response to proton pump inhibitors (PPI), upper endoscopy, and ambulatory reflux testing. Each of these has limitations of which the clinician must be aware when managing patients with reflux symptoms. Ambulatory reflux monitoring, in particular, can potentially document the true presence of pathologic GERD. Consequently, reflux testing is often necessary in our evaluation of patients with reflux symptoms, and can be useful in distinguishing etiologies driving a lack of response to PPI therapy. Reflux testing results can be also used to guide appropriate PPI prescribing and clinical decision making for appropriate or unnecessary therapy. This review focuses on the limitations of our current diagnostic paradigm and highlights how reflux testing can be helpful in the diagnosis and management of patients with poor response to PPI therapy.
Literature
1.
go back to reference Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.PubMedCrossRef Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.PubMedCrossRef
3.
go back to reference Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59:714–21.PubMedCrossRef Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59:714–21.PubMedCrossRef
4.
go back to reference •• Lacy BE, Chehade R, Crowell MD. A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11). Am J Gastroenterol. 2011;106:1604–11. This study provides comparative data between a widely used diagnostic questionnairea and pH testing for making a GERD diagnosis.PubMedCrossRef •• Lacy BE, Chehade R, Crowell MD. A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11). Am J Gastroenterol. 2011;106:1604–11. This study provides comparative data between a widely used diagnostic questionnairea and pH testing for making a GERD diagnosis.PubMedCrossRef
5.
go back to reference • Ribolsi M, Emerenziani S, Borrelli O, et al. Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients. Scand J Gastroenterol. 2012;47:1266–73. References 5 and 6 provide data suggesting a limited ability of baseine impedance measurements to diagnose GERD.PubMedCrossRef • Ribolsi M, Emerenziani S, Borrelli O, et al. Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients. Scand J Gastroenterol. 2012;47:1266–73. References 5 and 6 provide data suggesting a limited ability of baseine impedance measurements to diagnose GERD.PubMedCrossRef
6.
go back to reference • Heard R, Castell J, Castell DO, et al. Characterization of patients with low baseline impedance on multichannel intraluminal impedance-pH reflux testing. J Clin Gastroenterol. 2012;46:e55–7. References 5 and 6 provide data suggesting a limited ability of baseine impedance measurements to diagnose GERD.PubMedCrossRef • Heard R, Castell J, Castell DO, et al. Characterization of patients with low baseline impedance on multichannel intraluminal impedance-pH reflux testing. J Clin Gastroenterol. 2012;46:e55–7. References 5 and 6 provide data suggesting a limited ability of baseine impedance measurements to diagnose GERD.PubMedCrossRef
7.
go back to reference •• Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:1360–6. This recent paper calls into question the utility of the PPI test for diagnosing GERD.PubMedCrossRef •• Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:1360–6. This recent paper calls into question the utility of the PPI test for diagnosing GERD.PubMedCrossRef
8.
go back to reference Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383–91.PubMedCrossRef Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383–91.PubMedCrossRef
9.
go back to reference Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:249–56.PubMedCrossRef Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:249–56.PubMedCrossRef
10.
go back to reference •• Gawron AJ, Rothe J, Fought AJ, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10:620–5. This study found that a large proportion of patients continue PPI therapy even after negative reflux tests, and most are never told to attempt to stop therapy.PubMedCrossRef •• Gawron AJ, Rothe J, Fought AJ, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10:620–5. This study found that a large proportion of patients continue PPI therapy even after negative reflux tests, and most are never told to attempt to stop therapy.PubMedCrossRef
11.
go back to reference Sonnenberg A, Amorosi SL, Lacey MJ, et al. Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database. Gastrointest Endosc. 2008;67:489–96.PubMedCrossRef Sonnenberg A, Amorosi SL, Lacey MJ, et al. Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database. Gastrointest Endosc. 2008;67:489–96.PubMedCrossRef
12.
go back to reference • Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper Endoscopy for Gastroesophageal Reflux Disease: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2012:808–16. This paper outlines the best practices of using upper endoscopy in efforts to avoid over-utilization. • Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper Endoscopy for Gastroesophageal Reflux Disease: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2012:808–16. This paper outlines the best practices of using upper endoscopy in efforts to avoid over-utilization.
13.
go back to reference Rubenstein JH, Mattek N, Eisen G. Age- and sex-specific yield of Barrett’s esophagus by endoscopy indication. Gastrointest Endosc. 2010;71:21–7.PubMedCrossRef Rubenstein JH, Mattek N, Eisen G. Age- and sex-specific yield of Barrett’s esophagus by endoscopy indication. Gastrointest Endosc. 2010;71:21–7.PubMedCrossRef
14.
go back to reference Dickman R, Mattek N, Holub J, et al. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol. 2007;102:1173–9.PubMedCrossRef Dickman R, Mattek N, Holub J, et al. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol. 2007;102:1173–9.PubMedCrossRef
15.
go back to reference Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71:28–34.PubMedCrossRef Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71:28–34.PubMedCrossRef
16.
go back to reference Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10:1066–78.PubMedCrossRef Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10:1066–78.PubMedCrossRef
17.
go back to reference Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20.PubMedCrossRef Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20.PubMedCrossRef
18.
go back to reference Spergel JM, Book WM, Mays E, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr. 2011;52:300–6.PubMedCrossRef Spergel JM, Book WM, Mays E, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr. 2011;52:300–6.PubMedCrossRef
19.
go back to reference Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol. 2011;106:1439–45.PubMedCrossRef Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol. 2011;106:1439–45.PubMedCrossRef
20.
go back to reference Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc. 2009;69:917–30. 930 e1.PubMedCrossRef Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc. 2009;69:917–30. 930 e1.PubMedCrossRef
21.
go back to reference Hungin APS, Hill C, Molloy-Bland M, et al. Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:109–16.PubMedCrossRef Hungin APS, Hill C, Molloy-Bland M, et al. Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:109–16.PubMedCrossRef
22.
go back to reference Gunaratnam NT, Jessup TP, Inadomi J, et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473–7.PubMedCrossRef Gunaratnam NT, Jessup TP, Inadomi J, et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473–7.PubMedCrossRef
23.
go back to reference Lee RD, Mulford D, Wu J, et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010;31:1001–11.PubMed Lee RD, Mulford D, Wu J, et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010;31:1001–11.PubMed
24.
go back to reference Howden CW, Ballard ED, Koch FK, et al. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. J Clin Gastroenterol. 2009;43:323–6.PubMedCrossRef Howden CW, Ballard ED, Koch FK, et al. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. J Clin Gastroenterol. 2009;43:323–6.PubMedCrossRef
25.
go back to reference Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24:923–36.PubMedCrossRef Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24:923–36.PubMedCrossRef
26.
go back to reference Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2012;108:18–37.PubMedCrossRef Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2012;108:18–37.PubMedCrossRef
27.
go back to reference Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61:1340–54.PubMedCrossRef Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61:1340–54.PubMedCrossRef
28.
go back to reference Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut. 2003;52:464–71.PubMedCrossRef Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut. 2003;52:464–71.PubMedCrossRef
29.
go back to reference Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA agonsit baclofen in patients with symptoms and duoedeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52:1397–402.PubMedCrossRef Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA agonsit baclofen in patients with symptoms and duoedeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52:1397–402.PubMedCrossRef
30.
go back to reference Bell RCW, Mavrelis PG, Barnes WE, et al. A prospective multicenter registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication. J Am Coll Surg. 2012;215:794–809.PubMedCrossRef Bell RCW, Mavrelis PG, Barnes WE, et al. A prospective multicenter registry of patients with chronic gastroesophageal reflux disease receiving transoral incisionless fundoplication. J Am Coll Surg. 2012;215:794–809.PubMedCrossRef
31.
go back to reference Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ. 1999;319:550–3.PubMedCrossRef Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ. 1999;319:550–3.PubMedCrossRef
32.
go back to reference Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11:765–73.PubMedCrossRef Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11:765–73.PubMedCrossRef
33.
go back to reference van Pinxteren B, Sigterman KE, Bonis P, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010. van Pinxteren B, Sigterman KE, Bonis P, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010.
34.
go back to reference Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323–32.PubMedCrossRef Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323–32.PubMedCrossRef
35.
go back to reference Savarino E, Tutuian R, Zentilin P, et al. Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. Am J Gastroenterol. 2009. Savarino E, Tutuian R, Zentilin P, et al. Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. Am J Gastroenterol. 2009.
36.
go back to reference Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006.
37.
go back to reference Ostini R, Jackson C, Hegney D, et al. How is medication prescribing ceased? A systematic review. Med Care. 2011;49:24–36.PubMedCrossRef Ostini R, Jackson C, Hegney D, et al. How is medication prescribing ceased? A systematic review. Med Care. 2011;49:24–36.PubMedCrossRef
39.
go back to reference Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772–8.PubMedCrossRef Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772–8.PubMedCrossRef
40.
go back to reference Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784–90.PubMedCrossRef Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784–90.PubMedCrossRef
41.
go back to reference Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170:765–71.PubMedCrossRef Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170:765–71.PubMedCrossRef
42.
go back to reference Richter JE, Penagini R, Pohl D, et al. Barrett’s esophagus: proton pump inhibitors and chemoprevention II. Ann N Y Acad Sci. 2011;1232:114–39.PubMedCrossRef Richter JE, Penagini R, Pohl D, et al. Barrett’s esophagus: proton pump inhibitors and chemoprevention II. Ann N Y Acad Sci. 2011;1232:114–39.PubMedCrossRef
43.
go back to reference FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 2012:Safety Announcement [02–08–2012]. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 2012:Safety Announcement [02–08–2012].
44.
go back to reference • Nguyen TMT, Eslick GD. Systematic review: the treatment of noncardiac chest pain with antidepressants. Aliment Pharmacol Ther. 2012;35:493–500. This paper provides the available, albeit limited, data on treating non-cardiac chest pain with anti-depressants.PubMedCrossRef • Nguyen TMT, Eslick GD. Systematic review: the treatment of noncardiac chest pain with antidepressants. Aliment Pharmacol Ther. 2012;35:493–500. This paper provides the available, albeit limited, data on treating non-cardiac chest pain with anti-depressants.PubMedCrossRef
45.
go back to reference • Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol. 2012;107:372–8. This paper provides data suggesting a non-pharmacologic approach may be beneficial in certain patients with GERD.PubMedCrossRef • Eherer AJ, Netolitzky F, Högenauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol. 2012;107:372–8. This paper provides data suggesting a non-pharmacologic approach may be beneficial in certain patients with GERD.PubMedCrossRef
46.
go back to reference Kiebles JL, Kwiatek MA, Pandolfino JE, et al. Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. Dis Esophagus. 2010;23:545–53.PubMedCrossRef Kiebles JL, Kwiatek MA, Pandolfino JE, et al. Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. Dis Esophagus. 2010;23:545–53.PubMedCrossRef
47.
go back to reference Richter JEE, Pandolfino JEE, Vela MFF, et al. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the Esophageal Diagnostic Working Group. Dis Esophagus. 2012. Richter JEE, Pandolfino JEE, Vela MFF, et al. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the Esophageal Diagnostic Working Group. Dis Esophagus. 2012.
Metadata
Title
Ambulatory Reflux Monitoring in GERD – Which Test Should be Performed and Should Therapy be Stopped?
Authors
Andrew J. Gawron
John E. Pandolfino
Publication date
01-04-2013
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 4/2013
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-013-0316-6
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.